Claims for Patent: 10,159,745

Summary for Patent: 10,159,745

Title:	Tubulysin derivatives
Abstract:	Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
Inventor(s):	Gingipalli; Lakshmaiah (Waltham, MA), Toader; Dorin (Gaithersburg, MD), Wang; Fengjiang (Waltham, MA)
Assignee:	MedImmune, LLC (Gaithersburg, MD)
Application Number:	15/230,918
Patent Claims:	1. A method of making an antibody-drug conjugate comprising: contacting an antibody with a compound of Formula (II): ##STR00112## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is CH.sub.3 or CH.sub.2CH.sub.3; R.sup.2 is H or CH.sub.3; R.sup.4 is CH.sub.3, (CH.sub.2).sub.4NH.sub.2, or (CH.sub.2).sub.3NHC(.dbd.O)NH.sub.2; R.sup.5 is H or CH(CH.sub.3)(CH.sub.3); R.sup.6 is NHC(.dbd.O) or CH.sub.2; n is 1 or 2; and m is 0, 1, 2, or 3; under conditions sufficient to covalently conjugate the compound of Formula (II) to the antibody. 2. The method of claim 1, wherein the compound of Formula (II) is conjugated via a reactive thiol group of the antibody. 3. The method of claim 1, wherein the antibody is a monoclonal antibody. 4. The method of claim 1, wherein the antibody is specific to a cancer antigen. 5. The method of claim 1, wherein the antibody is alemtuzumab, bevacizumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab, or trastuzumab. 6. The method of claim 1, wherein n is 1 and R.sup.1 is methyl. 7. The method of claim 1, wherein R.sup.2 is methyl. 8. The method of claim 1, wherein R.sup.4 is (CH.sub.2).sub.4NH.sub.2. 9. The method of claim 1, wherein R.sup.5 is H. 10. The method of claim 1, wherein R.sup.6 is CH.sub.2. 11. The method of claim 1, wherein m is 1. 12. The method of claim 1, wherein n is 1, m is 1, R.sup.1 is methyl, R.sup.2 is methyl, R.sup.4 is (CH.sub.2).sub.4NH.sub.2, R.sup.5 is H, and R.sup.6 is CH.sub.2. 13. The method of claim 1, wherein the compound has the Formula (IIi): ##STR00113## 14. The method of claim 1, wherein the compound has the Formula (IIii): ##STR00114## 15. The method of claim 1, wherein the compound has the Formula (IIiii): ##STR00115## 16. A method of making an antibody-drug conjugate comprising: contacting an antibody with a compound of Formula (IIiv): ##STR00116## or a pharmaceutically acceptable salt thereof, under conditions sufficient to covalently conjugate the compound of Formula (IIiv) to the antibody. 17. A method of treating cancer by administering to a subject suffering from cancer, an effective amount of an antibody-drug conjugate which is a conjugate of a compound of the Formula (IIi): ##STR00117## of the Formula (IIii): ##STR00118## of the Formula (IIiii): ##STR00119## or of the Formula (IIiv): ##STR00120## 18. The method of claim 17, wherein the subject is suffering from squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, glioma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial carcinoma, myeloma, salivary gland carcinoma, kidney cancer, basal cell carcinoma, melanoma, prostate cancer, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, head and neck cancers, mucinous ovarian cancer, cholangiocarcinoma or renal papillary carcinoma.

Details for Patent 10,159,745

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2034-04-11
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2034-04-11
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2034-04-11
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2034-04-11
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2034-04-11
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2034-04-11